Answers are grounded in this paper and cite their sources.
Background Nusinersen treatment of adults with 5q-SMA was found to be safe and stabilizes or improves motor function in the short-term (<38 months), but data examining longer-term (>38 months) impact and safety is lacking. Objective To study the long-term (24-60 months) effects and safety profile of nusinersen in adults with 5q-SMA. Methods We conducted a observational study of 5q-SMA patients, age ≥18 years, and receiving nusinersen for ≥24 months. Data were analyzed by ambulatory status. Clinical outcomes included: 6-minute walk test (6MWT), Hammersmith Functional Motor Scale - Expanded (HFMSE) scores, revised upper limb module (RULM) scores, pulmonary function test results, and medication-related adverse effects. Data were collected at baseline and post-treatment initiation at months 2, 6, 12, 24, 36, 48, and 60 +/- 2 months. Linear mixed models with random intercept for each patient were used to examine the changes of outcomes across time. Results Thiry-two individuals with 5q-SMA (17 female) were included. Nineteen were non-ambulatory (mean age 38.3+/- 12.1 years) and 13 were ambulatory (mean age 32.9+/-9.5 years) at treatment onset. Average treatment duration was 53.3 months (range 24-60 months). The ambulatory group showed stability in 6MWT and HFMSE compared to baseline. In non-ambulatory patients, RULM and FVC remained stable. No serious adverse events attributable to nusinersen were reported. Conclusions Long-term nusinersen treatment is safe in adults with SMA. Patients showed relative clinical stability over 60 months. These findings suggest that nusinersen may provide relative improvement compared to the natural disease progression over 2-5 years of treatment.
No takes yet. Share an insight, caveat, or question.
Allen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: